Medtronic Bets On Blockbuster Hypertension Market With Ardian Acquisition

Medtronic's $800-million-plus bet on still-early-stage catheter technology for treating hypertension is a risk worth taking, company watchers suggest, considering many of the device giant's core offerings are in mature markets with paltry growth prospects.